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Abstract 
A total of 287 patients were treated with various antiviral therapy options: group I – 
basic (pathogenetic and symptomatic) therapy, group II – pegylated interferon in combination 
with ribavirin, group III – pegylated interferon with ribavirin and sofosbuvir, group IV – 
direct-acting antivirals. Patients with chronic viral hepatitis C (CVHC) before the start of 
treatment showed a decrease in platelet counts, segmented neutrophils and an increase in level 
of lymphocytes, bilirubin content, alanine aminotransferase activity, aspartate, transferrinase 
(practice), with a comparison group (practically virus-free patients) <0.05. After 4 weeks of 
receiving interferon-containing therapy, a further decrease was observed: leukocyte count, 
erythrocyte count, platelet count; ALT, AST and gamma-glutamyltranspeptidase (GGTP) 
activity; increased erythrocyte sedimentation rate (ESR), bilirubin content, and bilirubin 
activity p< 0.05. Patients who received direct-acting antivirals (DAAs) had a decrease in: 
erythrocyte count, total bilirubin content, ALT activity, AST, GGTP; increase in sed rate and 
the AST/ALT ratio, p <0.05. After 12 weeks of treatment, patients treated with pegylated 
interferon were diagnosed with a decrease in platelet count, erythrocyte count, and leukocyte 
count (with the exception of patients with dual therapy that experienced the slight increase of 
the leukocytes) with hemoglobin content, p <0.05. Also, in the group II subjects compared 
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with week 4 decreased: the content of bilirubin and creatinine, the activity of ALT, AST, 
GGTP, while the De Ritis ratio increased (p <0.05). Patients in group III had lower GGTP 
activity than at 4 weeks and lower ALT and AST values compared with the onset of  antiviral 
therapy (p <0.05). Patients receiving DAAs experienced a decrease in hemoglobin content; no 
changes in biochemical parameters at this stage compared with the previous one were 
established. 
The investigated integrative indicators suggest changes in the immune system of 
patients, in particular the prevalence of cellular immunity over the humoral link and the 
predominance of the autoimmune component. Patients with dual and triple PVT regimens had 
more pronounced changes compared to patients receiving DAAs. 
Keywords: chronic viral hepatitis C; clinical blood test; biochemical blood test; 
integrative parameters; immunity. 
 
Introduction. Around the world, about 71 million people are infected with the 
hepatitis C virus. However, the use of antiviral drugs can cure this infection, which reduces 
the risk of death from cirrhosis and hepatocellular carcinoma (HCC) [1]. 
Prior to synthesizing DAAs by standards of care for patients with chronic HCV 
infection, pegylated interferon (PEG-IFN) preparations in combination with ribavirin were 
used during 24 or 48 weeks depending on the genotype. This treatment was not only costly 
but also had significant side effects. These factors led to a decrease in the number of patients 
fully completing the treatment [2]. Currently, the need to administer antiviral therapy to all 
patients who have not received treatment and had no contraindication to therapy has been 
demonstrated [3]. The use of DAAs can reduce CVD prevalence and liver disease-related 
mortality by 94% and 75% in countries such as Egypt with high infection rates, so it can be 
treated as cost-effective for health care [4, 5]. The primary goal of HCV therapy is treatment 
until a stable virological response is defined, which is defined as HCV negative RNA within 
12 or 24 weeks after completion of treatment, with a very low likelihood of late relapse. 
Treatment response is usually associated with normalization of enzyme levels, improvement 
or disappearance of inflammation and liver fibrosis (in patients without cirrhosis). Positive 
dynamics are observed after treatment and in patients with severe fibrosis (F3) or cirrhosis 
(F4), which reduces the risk of life-threatening complications (portal hypertension and liver 
failure). According to recent data, in patients with liver cirrhosis, which does not show viral 
RNA, the risk of HCC morbidity and mortality associated with liver function is significantly 
reduced, but not completely eliminated, compared with untreated patients [3, 6-8]. 
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The aim of the study. To determine the dependence of changes in hematological, 
biochemical and integrative parameters in patients with chronic viral hepatitis C on the 
received antiviral therapy.  
Patients and methods.  
For the study, 287 patients were diagnosed with CVHC who were undergoing 
treatment at the Z. Y. Krasovytskyi Sumy Regional Infectious Clinical Hospital in the period 
from 2015 to 2019. Their medical records of inpatients and outpatients were also analyzed. 
The comparison group included 55 practically virus-free individuals who underwent a 
preventive medical examination at SSU University Clinic in 2018-2019. Patients were divided 
into 4 groups. 46.64% (131 individuals) of CVHC patients received basic (pathogenetic and 
symptomatic) therapy (group I), 54.36% (156) received antiviral therapy, including those 
treated with: a double regimen (PEG-IFN + ribavirin; group II) - 53.84% (84); triple (PEG-
IFN + ribavirin + sofosbuvir; group III) 16.03% (25); bezinterferon (DAAs; group IV) 
30.13% (47). 
The patients were subjected to a clinical blood test (Elite 3, CobasMicros), a 
biochemical blood test (ChemWell, COBASEMira) before starting at the 4th and at the 12th 
week of antiviral therapy. PCR to confirm the diagnosis and to establish the genotype of the 
virus and to determine the fibrosis using FIBROTEST (METAVIR) was performed in the 
commercial laboratory "SINEVO". Integrative indices (integral severity index - ISI, entropy 
of leukocyte formula), indices of nonspecific reactivity (resistance coefficient - RC, 
immunoreactivity index - IR, neutrophil-lymphocyte ratio -NLR, lymphocyte-monocyte ratio 
- LMR , lymphocyte index - Ilymph, eosinophils-lymphocytes ratio - ELR, index of 
allergization - IA, nuclear index - NI); indexes of activity of inflammation (total index of 
inflammation - TII, Krebs index - KI, lymphocytic-granulocytic index - ILG, index of 
leukocyte and ESR ratio - ILESR), indexes of intoxication (leucocyte intoxication index - LII, 
aggression index – Iagr, hematological index of intoxication - HII, leukocyte shift index - LSI, 
index of intoxication severity - IIS, reactive response of neutrophils- NRR) were calculated.  
The study materials were subjected to statistical analysis using nonparametric analysis 
methods. Accumulation, correction, systematization of the source information and 
visualization of the obtained results were performed in Microsoft Office Excel spreadsheets 
2016. Statistical analysis was performed using IBM SPSS Statistics v.23 (IBM Corporation). 
Quantitative indicators were evaluated for compliance with the normal distribution with the 
use of the Shapiro-Wilk test (with fewer than 50 tested) or the Kolmogorov-Smirnov test 
(with more than 50 tested). The sets of quantitative indicators were described using the values 
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of the median (Me) and the lower and upper quartiles (Q1-Q3). To compare independent sets 
in the absence of signs of normal data distribution, the Mann-Whitney U-test was used. We 
used the Wilcoxon W-test to compare the differences between two dependent paired samples. 
Results. Among the CVHC survey, the number of men was 1.96 times higher 
(66.20%) than women (33.80%). The age of patients in the general group comprised 46 (36-
55) years. 
In each group with different antiviral therapy schemes, the majority were also men 
(respectively group I - 60.31%, II - 66.67%, III - 84.00%, IV - 63.83%). Patients in all study 
groups were young and middle-aged: group I- 47,00 (37,00 - 58,00), II – 41,00 (32,25 - 
51,00), III – 41,00 (34,00 - 47,00), IV - 50,00 (40,00 - 60,00). 
Body mass index in all groups corresponded to the value of normal or excess body 
weight (respectively group I – 26,00 (24,00 – 29,00), II – 26,00 (23,25-29,00), III - 24,00 (23-
28,00), IV – 26,00 (24,00-29,00)). Disease duration after diagnosis in most patients was less 
than 10 years: basic therapy - 2,00 (1,00-6,00), double - 6.00 (5,00 – 8,75), triple – 5,00 ( 
3,00-7,00), non-interferon – 2,00 (2,00 – 6,00). 
In all groups individuals with 1st and 3rd genotype prevailed (respectively, group I - 
38.90% and 44.30%, II - 64.30% and 31.00%, III - 72.00% and 24.00%, IV - 57.40 and 
27.70%). Most patients in each group had minimal activity (respectively, I - 73.3%, II - 
75.00%, III - 68.00% and IV - 72.30%). 
In patients from the groups who were prescribed antiviral therapy, the greatest number 
were patients with moderate liver fibrosis (double - 35.70%, triple - 40.00%, DAAs - 31.9%). 
Among patients receiving basic therapy, severe liver fibrosis (37.40%) prevailed, moderate 
fibrosis occupied the second position (27.50%). 
In terms of epidemiological features, the distribution in the groups was homogeneous. 
The most widespread probable ways of infection were treatment at the dentist (accordingly 
group I - 76,34%, ІІ - 54,76%, ІІІ - 64,00%, ІV - 29,79%), surgical interventions and 
manipulations (accordingly basic therapy - 74,81%, double - 55,95%, triple - 44,00%, non-
interferon - 44,68%). Less likely cases were manipulations in beauty salons (respectively 
group I - 26.72%, II - 30.95%, III - 28.00%, IV - 8.51%), transfusions of blood components 
(respectively basic therapy - 29 , 77%, double - 27.38%, triple - 16.00%, non-interferon - 
17.02%). 
The total number of leukocytes and erythrocytes in all surveyed, regardless of the 
group, was normal before the start of treatment and did not differ from the values of 
practically virus-free patients. The hemoglobin level was also within the physiological 
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fluctuations, but had a slight difference in patients in different groups: compared to patients 
who did not receive antiviral therapy, the hemoglobin level was 1.1 times higher in the group 
I and II patients. The average platelet count in patients with CVHC was lower than in the 
comparison group (1.2-1.3 times). The ratio of rod-core and segment-nucleotrophils differed 
1.1-2.0 times in groups with a tendency to decrease the content of segment-nucleotrophils in 
patients. The lymphocyte content of the subjects was higher than in the comparison group. 
In different groups of patients before antiviral therapy, laboratory parameters did not 
differ from patients not receiving antiviral therapy, but erythrocyte and hemoglobin levels 
were slightly higher (1.1-1.2 and 1.1 times, respectively) in the double, triple and non-
interferon-treated groups. Also, the content of rod-neutrophils was 1.6-2.5 times lower. The 
number of segmented nuclear neutrophils and monocytes was only slightly lower in patients 
with dual therapy (1.1 and 1.3, respectively), and ESR in patients in group III (2.3) (Table 1). 
In patients undergoing dual antiviral therapy after 4 weeks of treatment, the number of 
leukocytes and segmented nuclei decreased by 1.5 and 1.2 times, respectively; ESR, the 
number of rod, lymphocytes, monocytes, and neutrophils increased 1.3, 1.7, 2.2 and 1.7 times, 
respectively. Indicators of red blood changed as follows: the content of hemoglobin and 
erythrocytes decreased 1.1 times, platelets - 1.2 times); however, it remained lower (1.2 times) 
than before treatment. When compared with the results at 4 weeks, the leukocyte formula 
changed: segmental nucleotrophils increased (by 1.1 times), and lymphocytes decreased by 
1.1 times, but compared with the beginning of therapy, rod-nuclear neutrophils increased (by 
1.3 times) and lymphocytes (by 1.2 times), and eosinophils were halved. The level of 
hemoglobin and erythrocytes was 1.2 times lower than before antiviral therapy and 1.1 times 
compared to week 4, platelets - 1.3 times relative to baseline and 1.1 at comparison with week 
4. The ESR has decreased (1.2 times) from the previous level, but was higher (1.9 times) 
compared to the initial value. The same dynamics of change during the passage of patients 
antiviral therapy has been presented by other researchers [10]. 
In patients with triple antiviral therapy, the results of the clinical blood test did not 
differ from the group with basic therapy, except for erythrocytes (in group III more than 1.1 
times), hemoglobin (more than 1.2), rod-nuclear neutrophils (more than 2.5) and ESR (over 
1.8). 
After 4 weeks of treatment in patients from group II there was a decrease in the total 
number of leukocytes by 1.6 times, erythrocytes and hemoglobin by 1.1 times, ESR increased 
by 2.8 times. In leukocyte formula, the level of rod-neutrophils increased 2.5 times, 
lymphocytes 1.3 times, and the number of segmented nuclear neutrophils decreased 1.1 times. 
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In patients receiving triple therapy, after 12 weeks of therapy compared to 4 weeks, the 
total number of leukocytes, erythrocytes, hemoglobin decreased by 1.1 times, platelets - by 
1.2 times. 8 times, erythrocytes, platelets and the content of hemoglobin - in 1,2, the number 
of segmented nuclear neutrophils in 1,1 times, increase in the number of rod-nuclear 
neutrophils 2.5 times, lymphocytes - 1.3 times, acceleration of  ESR - 3.2 times. Other studies 
show that widespread side effects of dual interferon-containing therapy are reduced 
erythrocytes, leukocytes, and platelets [11-13]. 
Patients did not show any differences from those who did not receive specific therapy, 
except for more erythrocytes and smaller - rod-shaped neutrophils, before initiating DAAs. 
After administration of DAAs for a month, the number of erythrocytes decreased and 
ESR increased in patients, after three months compared to 4 weeks and with the start of 
antiviral therapy, the hemoglobin content decreased. 
In the biochemical analysis of blood in the course of treatment, patients were 
diagnosed with some features in groups. In group I, compared with healthy, the amount of 
total bilirubin increased (by 1.2 times), ALT activity (by 2.4), AST (by 2.1), GGTP (by 1.8), 
and decreased ALP (by 1.1), which is explained by the predominant severity of cytolytic 
syndrome compared with cholestatic. The changes were similar in patients from different 
groups before starting treatment, except for higher level of protein in the groups with triple 
and non-interferon treatment regimens (Table 2). 
In patients undergoing double therapy after 4 weeks of treatment compared to the 
beginning of therapy, the amount of total bilirubin increased 1.4 times and the activity of ALP 
also growed, but the level of ALT decreased 1.4 times, AST - 1.2, GGTP - 1.1, which 
indicates a decrease in the intensity of cytolysis and increased cholestatic component. At this 
stage an increase in creatinine concentration (by 1.1 times) and a decrease in glucose content 
(by 1.1) were observed. Other studies have reported an increase in glucose tolerance after 
hepatitis C virus eradication [9].  
After 12 weeks of treatment in patients in group II compared to 4 weeks there was a 
decrease in the amount of total bilirubin (by 1.2 times), ALT activity (1.6), AST (1.3), GGTP 
(1.4), creatinine (1.1), glucose (1.1), with ALT, AST, and GGTP levels lower than those before 
treatment (correspondingly 2.2 times; 1.6; 1.5), with ALT and AST levels higher than normal 
(1.4 and 1.2). During this period, an increase in the De Ritis Ratio compared to 4 weeks (1.2) 
and with the beginning of antiviral therapy (1.3) was observed. 
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Table 1 - Changes in clinical blood analysis in patients with CVHC on the received antiviral therapy 
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Continuation of Table 1 






















































































































































































































































































































Notes. Significant difference compared to: * - indicator of group of practically virus-free individuals (р1˂0,05, calculated according to the Mann-Whitini criterion); 
** - with indicator in the group that did not receive antiviral therapy (p2˂0.05, calculated according to the Mann-Whitney criterion), *** - with indicator before 




Table 2 - Changes in the biochemical analysis of blood in patients with CVHC on the received antiviral therapy 
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Continuation of Table 2 
































































































































































































































Notes. Significant difference compared to: * - indicator of group of practically virus-free individuals (р1˂0,05, calculated according to the Mann-Whitini criterion); 
** - with indicator in the group that did not receive antiviral therapy (p2˂0.05, calculated according to the Mann-Whitney criterion), *** - with indicator before 
therapy (p3˂0.05, calculated according to Wilcoxon criterion), * *** - with an indicator after 4 weeks of antiviral therapy (p4˂0.05, calculated according to 
Wilcoxon criteria). 
 187 
Among patients on triple therapy after 4 weeks of treatment, the total bilirubin increased 1.2 
times and the De Ritis ratio 1.5 times, the ALT activity decreased 1.8 times, the AST and GGTP - 1.4 
times. 
After 12 weeks of therapy, the level of GGTP decreased 1.4 times compared to 4 weeks, other 
indicators remained at the previous level. However, compared to the beginning of treatment, ALT 
decreased 1.5 times, AST 1.3 times, and GGTP 2 times. 
In patients from group IV after 4 weeks of therapy the amount of total bilirubin decreased by 
1.1 times, ALT activity - 3.0, AST - 1.8, GGTP - 1.6, ALP - 1.3, and the De Ritis ratio increased 1.6 
times. Normalization of ALT and AST was observed in other studies, but bilirubin reduction was only 
found in patients with combination of sofosbuvir with symprevir [14]. At 12 weeks of treatment, the 
values of all biochemical parameters did not differ from the previous levels, but the activity of ALT, 
AST, GGTP, ALP were significantly lower, and the De Ritis ratio was higher than at the beginning of 
therapy. 
In groups of patients with CVHC, IST and entropy levels were higher than in the comparison 
group, which is explained by an increase in ESR and impaired normal ratios of leukocytes in patients. 
In patients at all stages of treatment, the following observations were made: increase in indices 
of nonspecific reactivity (RC - by 1.2-2.1 times) and inflammatory activity (ILG - by 1.2-2.0); 
decrease in indexes of endogenous intoxication (ISL – by 1.1-1.9), which confirms the prevalence of 
the autoimmune component of intoxication syndrome, and also indicates the severity of inflammation 
[15]. 
No changes in the levels of IR and LMR were observed, and other integrative indicators 
revealed changes depending on the type of therapy and the period of treatment. 
Patients from groups I, II, III and IV before receiving antiviral therapy had: increase of the 
following indices of nonspecific reactivity: RC (from 1.2 to 1.4 times), Ilymph (1.2-1.6), NI (1.4 
times), and in groups III and IV there was a decrease); decrease in NLR (1.1-1.3), ISEL (1.6-2). 
Among the indexes of activity of inflammation in these patients, an increase in TII (I - 1.2 times) or a 
decrease (II, III, IV - 1.1), an increase in KI (1.2-1.4) and ILESR (1.2–1.7), and decrease in ILG (1.2-
1.4) were established. Among the indexes of endogenous intoxication, only a decrease in ISL (1.2-1.3) 
and NRR (1.2-2.7) was found. 
In patients receiving dual antiviral therapy after 4 weeks of treatment, ISI (1.1) increased 
compared with pre-treatment data, but the entropy of leukocyte formula was normalized. Among non-
specific reactivity indices, the KI increased by 1.5 times, 1.4 - Ilymph, 1.9 - NI, there was a decrease in 
the NLR - by 1.7 times and ISEL - by 2.5, indicating an increase in the influence of cellular immunity, 
compared with humoral, and left shift in the granulocyte-macrophage system [15]. Among the 
inflammation activity indexes, increased: TII (1.1 times), ILG (1.4), ILESR (1.7); only KI (1.4) 
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decreased, confirming increased inflammation due to the autoimmune component [15]. Indices of 
endogenous intoxication decreased: 1.4 times - ISL and 1.9 - NRR. These data confirm the decrease in 
immunological reactivity with adequate treatment. 
After 12 weeks, ISI treatment increased by 1.1 times compared with 4 weeks and before 
treatment. The entropy of the leukocyte formula also went beyond normal (increased 1.2 times relative 
to 4 weeks). RC decreased during this period (1.3 times), but remained higher than normal and at the 
beginning of therapy. Also, when comparing to 4 weeks, the ILG (1.2 times) and NLR (1.1) increased, 
while the lower values were Ilimph (1.3), IA (1.2), NI (1.4), which indicates a weakening of cellular 
immunity at this stage. Among the indices of inflammatory activity, TII increased by 1.1 comparing to 
the 4th week and by 1.2 comparing to the beginning of therapy, KI increased by 1.2, but remained 
lower than before treatment, ILG decreased by 1.2, remaining higher than before therapy, ILESR 
increased by 1.6 compared with 4 weeks and by 2.7 than before therapy. All indexes of endogenous 
intoxication at the 12th week of therapy in comparison with 4 weeks increased (LII - by 1.3 times, Iagr 
- by 1.4, HII - by 1.6, LSI - by 1.2, IIS - by 2.1 ) and the NRR level has not changed. 
Patients in group III after 4 weeks of therapy had similar changes: ISI increased by 1.1 times, 
entropy of leukocyte formula decreased by 1.1 times. Among the nonspecific reactivity indices, the 
following indicators have changed: the KI increased 1.4 times, the Ilimph - 1.3, the NI - 2.8, and the 
ISEL decreased 1.3 times. Among the activity indexes, ILG inflammation increased one and a half 
times, ILESR 1.3 times, and KI decreased 1.3 times. From the indexes of endogenous intoxication, 
after 4 weeks of therapy, only ISL decreased by 1.5 times. 
At week 12 of treatment, there were some differences in the nonspecific reactivity indices: KI, 
Ilimf, and NI remained at the same level, but they were higher than values before therapy. Indices of 
activity of inflammation and endogenous intoxication did not change compared to week 4. 
In patients receiving interferon-free antiviral regimens, the ISI significantly increased at 4 
weeks and remained at the same level until the end of treatment, the entropy of the leukocyte formula 
was higher than in the comparison group, but did not change in the observation process as in the 
previous groups. All integrative indicators did not change during therapy except ILESR (increased by 
1.6 at 4 weeks of treatment).  
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Table 3 - Changes in integrative parameters in patients with CVHC on the received antiviral therapy 
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Continuation of Table 3 
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Notes. Significant difference compared to: * - indicator of group of practically virus-free individuals (р1˂0,05, calculated according to the Mann-
Whitini criterion); ** - with indicator in the group that did not receive antiviral therapy (p2˂0.05, calculated according to the Mann-Whitney criterion), *** - 
with indicator before therapy (p3˂0.05, calculated according to Wilcoxon criterion), * *** - with an indicator after 4 weeks of antiviral therapy (p4˂0.05, 
calculated according to Wilcoxon criteria). 
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1 In patients with CVHC, there is a predominance of young and middle-aged men 
without obesity.  In most cases, viral hepatitis is caused by 1b and 3a genotypes, and undergoes 
with minimal activity and moderate fibrotic changes in the liver. Among the probable ways of 
infection indicated by patients, the treatment of the dentist (29.79% - 76.34%), surgical 
interventions and manipulations (44.00% - 74.81%) predominate.  
2 There is a decrease in platelet counts and segmented neutrophils, as well as an 
increase in lymphocyte counts (p <0.05) in pre-treatment patients compared with healthy ones. 
After 4 weeks of treatment, the subjects receiving double and triple therapy reduced the number 
of leukocytes, erythrocytes, and ESR, and with double therapy - an additional number of 
platelets (p <0.05). With the use of DAAs, only erythrocyte content decreased after one month 
and ESR increased, and hemoglobin content decreased by 12 weeks (p <0.05). 
3 Before treatment, blood biochemical analysis is characterized by an increase in 
bilirubin concentration, ALT activity, AST (p <0.05). After the fourth week of treatment in 
patients undergoing dual and triple therapy, the activity of ALT, AST, GGTP decreased, while 
bilirubin and ALP increased (p <0.05). At 12 weeks, total bilirubin, ALT, AST, GGTP, creatinine 
decreased, but the De Ritis ratio increased (p <0.05). Patients on interferon-free therapy after 4 
weeks experience a decrease in the concentration of total bilirubin, the activity of ALT, AST, 
GGTP, ALP and increase the De Ritis ratio (p <0.05) that remains stable until the end of 
treatment.  
4 Changes in integrative parameters indicate the prevalence of cellular immunity, a 
clear inflammation with a predominance of the autoimmune component. In patients undergoing 
interferon-containing therapy, indicators demonstrating the dominance of cellular immunity are 
increased, and at 12 weeks are reduced. Indices that indicate inflammation of the autoimmune 
genesis remain elevated throughout the treatment period. People receiving DAAs have increased 
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